Managing IP survey: SPC framework

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Managing IP survey: SPC framework

biotech168

Managing IP is seeking views from in-house counsel at pharma and biotech companies on the state of the SPC framework in Europe; including Article 3a, the waiver and unitary SPCs

biotech200

You can take the survey here

Please only take the survey if you are an in-house lawyer from a pharmaceutical, biotech or life sciences company.


We are looking to gain and share insight on how in-house IP counsel view the SPC framework in Europe; including Article 3a, the SPC Manufacturing Waiver and unitary SPCs. 

This is the second in our series of in-house surveys in 2019. You can read the special report on the findings of that survey, on the changing dynamic between artificial intelligence and IP, here.

Don’t miss the chance to have your say.

The survey should take no longer than five minutes to complete, and all responses will only be published in an aggregated and anonymised form. The more responses we get, the more illuminating the final report will be.

If you would like to discuss your thoughts in more detail, please contact Patrick Wingrove at patrick.wingrove@managingip.com

more from across site and SHARED ros bottom lb

More from across our site

A new transatlantic firm under the name of Winston Taylor is expected to go live in May 2026, and is likely to have a significant impact on Europe’s IP market
Geoff Steward and Rebecca Newman of Addleshaw Goddard explain how they secured victory in a rare ‘genericide’ case and why the work went beyond the courtroom
Nancy Frandsen looks back on her career, from answering a paralegal advert to expanding RCCB’s ‘entrepreneurial’ IP practice as a partner
The tie-up could result in the firm’s German and France-based teams, which both have strong UPC expertise, becoming independent
News of a slowdown in the UK’s clean energy IP landscape and an EPO report on unitary patent uptake were also among the top talking points
Price hikes at ‘big law’ firms are pushing some clients toward boutiques that offer predictable fees, specialised expertise, and a model built around prioritising IP
The Australian side, in particular, can benefit by capitalising on its independent status to bring in more work from Western countries while still working with its former Chinese partner
Koen Bijvank of Brinkhof and Johannes Heselberger of Bardehle Pagenberg discuss the Amgen v Sanofi case and why it will be cited frequently
View the official winners of the 2025 Social Impact EMEA Awards
King & Wood Mallesons will break into two entities, 14 years after a merger between a Chinese and an Australian firm created the combined outfit
Gift this article